Radiomic Features Are Predictive of Response in Rectal Cancer Undergoing Therapy.

chemoradiotherapy locally advanced rectal cancer magnetic resonance imaging pathological complete response radiomic rectal cancer

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
02 Aug 2023
Historique:
received: 22 06 2023
revised: 14 07 2023
accepted: 19 07 2023
medline: 12 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

Rectal cancer is a major mortality cause in the United States (US), and its treatment is based on individual risk factors for recurrence in each patient. In patients with rectal cancer, accurate assessment of response to chemoradiotherapy has increased in importance as the variety of treatment options has grown. In this scenario, a controversial non-operative approach may be considered in some patients for whom complete tumor regression is believed to have occurred. The recommended treatment for locally advanced rectal cancer (LARC, T3-4 ± N+) is total mesorectal excision (TME) after neoadjuvant chemoradiotherapy (nCRT). Magnetic resonance imaging (MRI) has become a standard technique for local staging of rectal cancer (tumor, lymph node, and circumferential resection margin [CRM] staging), in both the US and Europe, and it is getting widely used for restaging purposes. In our study, we aimed to use an MRI radiomic model to identify features linked to the different responses of chemoradiotherapy of rectal cancer before surgery, and whether these features are helpful to understand the effectiveness of the treatments. We retrospectively evaluated adult patients diagnosed with LARC who were subjected to at least 2 MRI examinations in 10-12 weeks at our hospital, before and after nCRT. The MRI acquisition protocol for the 2 exams included T2 sequence and apparent diffusion coefficient (ADC) map. The patients were divided into 2 groups according to the treatment response: complete or good responders (Group 1) and incomplete or poor responders (Group 2). MRI images were segmented, and quantitative features were extracted and compared between the two groups. Features that showed significant differences (SF) were then included in a LASSO regression method to build a radiomic-based predictive model. We included 38 patients (26 males and 12 females), who are classified from T2 and T4 stages in the rectal cancer TNM. After the nCRT, the patients were divided into Group 1 (13 patients), complete or good responders, and Group 2 (25 patients), incomplete or poor responders. Analysis at baseline generated the following significant features for the Mann-Whitney test (out of a total of 107) for each sequence. Also, the analysis at the end of the follow-up yielded a high number of significant features for the Mann-Whitney test (out of a total of 107) for each image. Features selected by the LASSO regression method for each image analyzed; ROC curves relative to each model are represented. We developed an MRI-based radiomic model that is able to differentiate and predict between responders and non-responders who went through nCRT for rectal cancer. This approach might identify early lesions with high surgical potential from lesions potentially resolving after medical treatment.

Sections du résumé

BACKGROUND BACKGROUND
Rectal cancer is a major mortality cause in the United States (US), and its treatment is based on individual risk factors for recurrence in each patient. In patients with rectal cancer, accurate assessment of response to chemoradiotherapy has increased in importance as the variety of treatment options has grown. In this scenario, a controversial non-operative approach may be considered in some patients for whom complete tumor regression is believed to have occurred. The recommended treatment for locally advanced rectal cancer (LARC, T3-4 ± N+) is total mesorectal excision (TME) after neoadjuvant chemoradiotherapy (nCRT). Magnetic resonance imaging (MRI) has become a standard technique for local staging of rectal cancer (tumor, lymph node, and circumferential resection margin [CRM] staging), in both the US and Europe, and it is getting widely used for restaging purposes.
AIM OBJECTIVE
In our study, we aimed to use an MRI radiomic model to identify features linked to the different responses of chemoradiotherapy of rectal cancer before surgery, and whether these features are helpful to understand the effectiveness of the treatments.
METHODS METHODS
We retrospectively evaluated adult patients diagnosed with LARC who were subjected to at least 2 MRI examinations in 10-12 weeks at our hospital, before and after nCRT. The MRI acquisition protocol for the 2 exams included T2 sequence and apparent diffusion coefficient (ADC) map. The patients were divided into 2 groups according to the treatment response: complete or good responders (Group 1) and incomplete or poor responders (Group 2). MRI images were segmented, and quantitative features were extracted and compared between the two groups. Features that showed significant differences (SF) were then included in a LASSO regression method to build a radiomic-based predictive model.
RESULTS RESULTS
We included 38 patients (26 males and 12 females), who are classified from T2 and T4 stages in the rectal cancer TNM. After the nCRT, the patients were divided into Group 1 (13 patients), complete or good responders, and Group 2 (25 patients), incomplete or poor responders. Analysis at baseline generated the following significant features for the Mann-Whitney test (out of a total of 107) for each sequence. Also, the analysis at the end of the follow-up yielded a high number of significant features for the Mann-Whitney test (out of a total of 107) for each image. Features selected by the LASSO regression method for each image analyzed; ROC curves relative to each model are represented.
CONCLUSION CONCLUSIONS
We developed an MRI-based radiomic model that is able to differentiate and predict between responders and non-responders who went through nCRT for rectal cancer. This approach might identify early lesions with high surgical potential from lesions potentially resolving after medical treatment.

Identifiants

pubmed: 37568936
pii: diagnostics13152573
doi: 10.3390/diagnostics13152573
pmc: PMC10417449
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Clin Oncol. 2015 Apr;20(2):207-39
pubmed: 25782566
Jpn J Radiol. 2023 Jan;41(1):71-82
pubmed: 35962933
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
Semin Ultrasound CT MR. 2005 Aug;26(4):259-68
pubmed: 16152740
Radiographics. 2019 Mar-Apr;39(2):367-387
pubmed: 30768361
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Radiology. 2013 Oct;269(1):101-12
pubmed: 23801777
Ann Surg. 2010 Dec;252(6):998-1004
pubmed: 21107110
Radiographics. 2019 Mar-Apr;39(2):538-556
pubmed: 30844347
Am J Surg Pathol. 2005 May;29(5):602-6
pubmed: 15832083
J Clin Oncol. 2011 Oct 1;29(28):3753-60
pubmed: 21876084
Eur J Radiol. 2018 Feb;99:131-137
pubmed: 29362144
Abdom Radiol (NY). 2019 Nov;44(11):3549-3558
pubmed: 31062058
Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8
pubmed: 15383798
Clin Cancer Res. 2016 Nov 1;22(21):5256-5264
pubmed: 27185368
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):501-513
pubmed: 28479372
Int J Mol Sci. 2018 Aug 30;19(9):
pubmed: 30200215
Radiology. 2018 Jun;287(3):833-843
pubmed: 29514017
Semin Radiat Oncol. 2011 Jul;21(3):169-77
pubmed: 21645861
Am J Surg Pathol. 2004 Feb;28(2):215-23
pubmed: 15043311
Insights Imaging. 2021 Aug 9;12(1):114
pubmed: 34373961
Abdom Radiol (NY). 2018 Nov;43(11):2893-2902
pubmed: 29785540
Abdom Radiol (NY). 2021 Nov;46(11):5072-5085
pubmed: 34302510
Cancer Med. 2019 Dec;8(17):7244-7252
pubmed: 31642204
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
AJR Am J Roentgenol. 2012 Oct;199(4):W486-95
pubmed: 22997398
Ann Surg Oncol. 2012 Jul;19(7):2212-23
pubmed: 22271205

Auteurs

Diletta Santini (D)

Department of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Ginevra Danti (G)

Department of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Eleonora Bicci (E)

Department of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Antonio Galluzzo (A)

Department of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Silvia Bettarini (S)

Department of Health Physics, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Simone Busoni (S)

Department of Health Physics, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Tommaso Innocenti (T)

Clinical Gastroenterology Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Andrea Galli (A)

Clinical Gastroenterology Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Vittorio Miele (V)

Department of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Classifications MeSH